The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
A correction has been published: N Engl J Med 2002;346(18):1424.

Original Article
PreviousPrevious
Volume 346:1194-1199 April 18, 2002 Number 16
NextNext

Intravascular Gamma Radiation for In-Stent Restenosis in Saphenous-Vein Bypass Grafts
Ron Waksman, M.D., Andrew E. Ajani, M.D., R. Larry White, M.D., Rosanna C. Chan, M.D., Lowell F. Satler, M.D., Kenneth M. Kent, M.D., Augusto D. Pichard, M.D., Ellen E. Pinnow, M.S., Anh B. Bui, M.D., Steven Ramee, M.D., Paul Teirstein, M.D., and Joseph Lindsay, M.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-PowerPoint Slide Set

Commentary
-Perspective
 by Cannon, R. O.
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
-PubMed Citation
ABSTRACT

Background Intracoronary radiation therapy is effective in reducing the recurrence of in-stent stenosis in native coronary arteries. We examined the effects of intravascular gamma radiation in patients with in-stent restenosis of saphenous-vein bypass grafts.

Methods A total of 120 patients with in-stent restenosis in saphenous-vein grafts, the majority of whom had diffuse lesions, underwent balloon angioplasty, atherectomy, additional stenting, or a combination of these procedures. If the intervention was successful, the patients were randomly assigned in a double-blind fashion to intravascular treatment with a ribbon containing either iridium-192 or nonradioactive seeds. The prescribed dose, delivered at a distance of 2 mm from the source, was 14 to 15 Gy in vessels that were 2.5 to 4.0 mm in diameter and 18 Gy in vessels with a diameter that exceeded 4.0 mm. The primary end points were death from cardiac causes, Q-wave myocardial infarction, revascularization of the target vessel, and a composite of these events at 12 months.

Results Revascularization and radiation therapy were successfully accomplished in all patients. At six months, the restenosis rate was lower in the 60 patients assigned to the iridium-192 group than in the 60 assigned to the placebo group (21 percent vs. 44 percent, P=0.005). At 12 months, the rate of revascularization of the target lesion was 70 percent lower in the iridium-192 group than in the placebo group (17 percent vs. 57 percent, P<0.001), and the rate of major cardiac events was 49 percent lower (32 percent vs. 63 percent, P<0.001).

Conclusions The results of our study support the use of gamma-radiation therapy for the treatment of in-stent restenosis in patients with bypass grafts.


Source Information

From Washington Hospital Center and the Washington Cancer Institute at Washington Hospital Center, Washington, D.C. (R.W., A.E.A., R.L.W., R.C.C., L.F.S., K.M.K., A.D.P., E.E.P., A.B.B., J.L.); the Oschner Clinic, New Orleans (S.R.); and the Scripps Clinic, San Diego, Calif. (P.T.).

Address reprint requests to Dr. Waksman at the Division of Cardiology, Washington Hospital Center, 110 Irving St., NW, Suite 4B-1, Washington, DC 20010, or at ron.waksman{at}medstar.net.

Full Text of this Article


Related Letters:

Brachytherapy and Saphenous-Vein Grafts
Sharma S., Nyitray W., Bhambi B., Waksman R., Ajani A. E.
Extract | Full Text | PDF  
N Engl J Med 2002; 347:692-693, Aug 29, 2002. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.